Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.700
+0.130 (8.28%)
Nov 24, 2025, 4:00 PM EST - Market closed
Acumen Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
102.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 1.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABOS News
- 12 days ago - Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 3 months ago - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewsWire
- 4 months ago - JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire
- 4 months ago - Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025 - GlobeNewsWire